NL-OMON49856招募中2 期
STEPWISE Parkinson: A smartphone based, titrated exercise solution for patients with Parkinson*s disease in daily life - STEPWISE Parkinson
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 452
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1) idiopathic PD
- •2) Hoehn and Yahr 1-3
- •3) able to understand the Dutch language
- •4) able to walk independently
- •5) less than 120 minutes of sports/outdoor activities per day (question 5-28
- •LASA Physical Activity Questionnaire (LAPAQ))
- •6) takes less than 7.000 steps/day during 1-week baseline
排除标准
- •1) weekly falls in the previous 3 months
- •2) medical conditions that hamper mobility
- •3) living in a nursing home
- •4) cognitive impairments that hamper use of the motivational app on the
- •smartphone (Montreal Cognitive Assessment (MoCA <26)
- •5) not in the possession of a suitable smartphone (Iphone 5S or newer with iOS
- •10 or higher or Android 4.1 or newer)
研究者
相似试验
进行中（未招募）
2 期
COVID-19 vaccines in pregnancyCOVID-19 (SARS-CoV-2 infection)Infections and InfestationsISRCTN15279830St George's, University of London319
已完成
Unknown
A randomised, placebo-controlled, single blind, monocentric trial to investigate the influence of an artichoke leaf extract for the treatment of non-alcoholic fatty liver disease (NAFLD)E66.0K76.0Obesity due to excess caloriesFatty (change of) liver, not elsewhere classifiedDRKS00024706niversität des Saarlandes40
进行中（未招募）
1 期
A phase III, partially blind, randomised, primary vaccination study to assess the immunogenicity and safety of three different lots of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella vaccine (MeMuRu-OKA), when given as a two-dose schedule to healthy children in their second year of life. - MeMuRu-OKA 043Active immunization of healthy children during their second year of life against measles, mumps, rubella and varicella diseases.EUCTR2004-005123-18-FIGlaxoSmithKline1,442
进行中（未招募）
不适用
A phase III, partially blind, randomised, primary vaccination study to assess the immunogenicity and safety of three different lots of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella vaccine (MeMuRu-OKA), when given as a two-dose schedule to healthy children in their second year of life. - MeMuRu-OKA 043Active immunization of healthy children during their second year of life against measles, mumps, rubella and varicella diseases.EUCTR2004-005123-18-DEGlaxoSmithKline Biologicals1,442
已完成
Unknown
Phase 1 clinical trial to evaluate safety, tolerability and pharmacokinetic characteristics of CKR-051 after transdermal administration in healthy male subjectsDiseases of the skin and subcutaneous tissueKCT0008410CK Regeon52